Astellas touts women's health with PGA sponsorship; GSK preps for global PR review;

> Astellas Pharma is turning to the PGA Tour to get women talking about their health, teeing up a sponsorship of the PGA Tour Woman initiative for the second time; the program includes on-site events at tournaments and social media. Report (sub. req.)

> GlaxoSmithKline ($GSK) is starting a global review of its public relations, PRWeek reports, aiming to shuffle its current PR roster, which now includes Burson-Marsteller and GolinHarris. Report (sub. req.)

> Medivation ($MDVN) unveiled data on its prostate cancer drug Xtandi that could lead to its use in a broader market: patients with advanced disease who haven't yet had chemotherapy. Report

> Pharma's payments to doctors are a growing concern in the U.K., where a group of physicians, researchers and campaigners are urging disclosure of gifts and payments. Report

> Should drugmakers be wary of issuing press releases about negative trial data while similar trials are still ongoing? Report

And Finally... Can Big Data help drugmakers keep patients on their pills--and refills coming? Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.